10-Q: The Joint Corp. Q3 2025: Refranchising Drives Net Income

The Joint Corp. reported a net income of $1.9 million for the nine months ended September 30, 2025, driven by its refranchising strategy, despite a decrease in comparable same-store sales.

Summary

• Net income for the nine months ended September 30, 2025, was $1,916,168, a significant improvement from a net loss of $5,814,558 in the prior year.
• Net income from discontinued operations was $3,121,454 for the nine months ended September 30, 2025, contributing substantially to the overall profitability.
• Total revenues from continuing operations increased by $2.3 million (6.1%) to $39,728,545 for the nine months ended September 30, 2025.
• The company refranchised 38 company-owned or managed clinics during the nine months ended September 30, 2025, and plans to sell the remaining corporate portfolio, including 45 Southern California clinics to Elite Chiro Group for $4.5 million.
• Comparable same-store sales (Comp Sales) for clinics open at least 13 months decreased by 2.0% for the three months ended September 30, 2025.
• The Board of Directors authorized an additional $12.0 million for the stock repurchase program, extending it to November 4, 2027, after completing the initial $5.0 million authorization.
• A material weakness in internal controls over financial reporting related to accounting for non-routine transactions and impairment charges persists as of September 30, 2025.

Sentiment

Score: 6

Explanation: While the company achieved overall net income due to its refranchising strategy and showed revenue growth in continuing operations, the decline in comparable store sales and system-wide sales, coupled with persistent material weakness in internal controls and ongoing litigation, presents significant headwinds. The increased stock repurchase authorization is a positive for shareholders, but operational performance metrics show weakness.

Positives

• Achieved a net income of $1,916,168 for the nine months ended September 30, 2025, a significant improvement from a $5,814,558 net loss in the prior year.
• Total revenues from continuing operations increased by $2.3 million (6.1%) to $39,728,545 for the nine months ended September 30, 2025.
• Successful refranchising of 38 company-owned or managed clinics during the nine months ended September 30, 2025, generating $7.8 million in proceeds from clinic sales.
• Completed the initial $5.0 million stock repurchase program and authorized an additional $12.0 million, demonstrating commitment to shareholder returns.
• No outstanding balance on the Credit Agreement as of September 30, 2025, and the agreement was amended to consent to the refranchising strategy and extend maturity to August 31, 2027.
• Increased other income, net, by $285,082 (142.1%) for the nine months ended September 30, 2025, primarily due to higher interest income from cash and cash equivalents.

Negatives

• Net loss from continuing operations was $1,205,286 for the nine months ended September 30, 2025.
• Comparable same-store sales (Comp Sales) for clinics open at least 13 months decreased by 2.0% for the three months ended September 30, 2025.
• Comp sales for mature clinics (open 48 months or more) decreased by 4.9% for the three months ended September 30, 2025.
• System-wide sales for all clinics decreased by 1.5% to $127.3 million for the three months ended September 30, 2025.
• Selling and marketing expenses increased by $1.6 million (19.8%) for the nine months ended September 30, 2025, due to digital marketing transformation efforts.
• Net cash used in operating activities for both continuing and discontinued operations was $1,058,973 for the nine months ended September 30, 2025, a decrease of $6.3 million from the prior year's cash provided by operating activities.

Risks

• The nationwide labor shortage negatively impacts the ability to recruit chiropractors and other qualified personnel, which may limit growth strategy and reduce net revenues.
• Inflation, leading to increased labor costs and interest rates, as well as changes to import tariffs, may lead to reduced discretionary spending, negatively impacting the business.
• Inability to successfully implement the growth strategy if franchisees are unable to locate and secure appropriate sites, obtain favorable lease terms, and attract patients.
• Restatement of prior consolidated financial statements may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on stock price.
• Limited experience operating company-owned or managed clinics in geographic areas with few or no clinics, potentially hindering the ability to duplicate franchisee success.
• A material weakness in internal controls over financial reporting persists, potentially impacting the ability to accurately report financial results, prevent fraud, or maintain investor confidence.
• Failure to successfully design and maintain proprietary and third-party management information systems or implement new systems.
• Inability to continue selling franchises to qualified franchisees, or franchisees failing to develop profitable territories and clinics.
• New clinics may not reach profitability, and the company may not be able to maintain or improve revenues and franchise fees from existing franchised clinics.
• The chiropractic industry is highly competitive, with many well-established independent competitors, which could prevent market share increase or result in reduction.
• State administrative actions and rulings regarding the corporate practice of chiropractic and prepayment of chiropractic services may jeopardize the business model.
• Expected new federal regulations and state laws regarding joint employer responsibility could negatively impact the franchise business model, increasing potential liability.
• Increased regulatory focus on fair franchise practices could increase the risk of liability in disputes with franchisees and enforcement actions.
• Negative publicity or damage to reputation, which could arise from concerns expressed by opponents of chiropractic and by chiropractors operating under traditional service models.
• IT security systems and those of third-party service providers may be breached, leading to civil liability and diminished public perception.
• Legislation and regulations, as well as new medical procedures and techniques, could reduce or eliminate competitive advantages.
• Unfavorable global economic or political conditions, the financial impact of the U.S. government shutdown, and other cost increases could impact the business.
• Anticipation that 2025 will continue to be a volatile macroeconomic environment.
• Elevated interest rates may adversely affect patients' financial conditions, resulting in reduced spending on services.
• The likelihood of a loss related to multiple lawsuits filed against the Company in 2024 and 2025 in California became probable, alleging invasion of privacy, breach of fiduciary duty, and failure to provide a safe environment, with potential liability undetermined.

Future Outlook

The company plans to continue its rapid, franchise-focused expansion of chiropractic clinics in North America and potentially abroad, aiming to be the leading provider and most recognized brand. It anticipates 2025 will remain a volatile macroeconomic environment, with labor costs and elevated interest rates posing headwinds. The refranchising strategy is expected to generate value-creating capital allocation opportunities, including reinvestment in the brand, IT platforms, regional development territory repurchases, merger or acquisition opportunities, and additional stock repurchase programs.

Management Comments

• We will continue our rapid and franchised focused expansion of chiropractic clinics in key markets throughout North America, and potentially abroad, as we seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry.
• This refined strategy will leverage our greatest strength our capacity to build a franchise to drive long-term growth for both our franchisees and The Joint as a public company.
• We believe that we continue to have a sound business concept and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness.
• We anticipate that 2025 will continue to be a volatile macroeconomic environment.
• Our goal will be to generate significant processes that will provide us with value creating capital allocation opportunities.

Industry Context

The company operates in the chiropractic care industry, focusing on a private pay, non-insurance, cash-based model. It believes this model benefits from fundamental changes in how Americans access chiropractic care and a growing interest in affordable natural wellness solutions, aligning with chiropractors' preference to avoid insurance-based models. The refranchising strategy aims to leverage the company's franchising strength for long-term growth within this evolving market.

Management Changes

Corporate Governance

Legal Proceedings

• Settlement agreements from litigation related to employment matters of $1.5 million were entered during the second quarter of 2024, accrued in discontinued operations current liabilities. Payment is expected in Q1 2026.
• A medical injury claim filed on September 5, 2023, reached a settlement agreement on February 25, 2025, for $3.4 million, with $1.9 million offset by an insurance receivable. The settlement was paid in full during Q1 2025.
• Multiple lawsuits filed against the company in 2024 and 2025 in the State of California, alleging invasion of privacy, breach of fiduciary duty, and failure to provide a safe environment. The likelihood of a loss became probable in Q3 2025, but the outcome and any potential liability are not reasonably estimable, and no accrual exists as of September 30, 2025.

Related Party Transactions

• Mr. Jefferson Gramm, Managing Partner of Bandera Partners LLC and a beneficial holder of approximately 26% of the company's outstanding common stock, was appointed to the Board of Directors effective January 2, 2024.
• Marshall Gramm, a family member of Mr. Jefferson Gramm, owns four franchise licenses. One license was sold in December 2020 for $39,900, and three licenses were transferred in June 2022 for a transfer fee of $15,000 each plus prorated franchise license fees of $17,706 total. These transactions involved terms no less favorable to the company than those with unaffiliated parties.
• In October 2020, Mr. Jefferson Gramm loaned approximately $370,000 to an unaffiliated franchisee, with a remaining balance of approximately $215,000 as of September 30, 2025.

Stakeholder Impact

• Shareholders are positively impacted by the stock repurchase program and the overall net income, but potentially negatively by declining comparable sales and the material weakness in internal controls.
• Employees are impacted by changes in payroll and employee compensation expenses, and the departure of long-tenure employees.
• Franchisees benefit from the company's focus on franchise expansion and support, but face challenges from labor shortages and inflation.
• Customers (Patients) are potentially impacted by labor shortages affecting service quality and elevated interest rates reducing discretionary spending on services.
• Creditors are positively impacted by the company's compliance with debt covenants and no outstanding balance on the Credit Agreement.

Next Steps

• Continue rapid and franchise-focused expansion of chiropractic clinics in key markets throughout North America, and potentially abroad.
• Refranchise the balance of the corporate clinic portfolio, with the Elite Chiro Group Transaction for 45 Southern California clinics expected to close on or before November 25, 2025.
• Generate value-creating capital allocation opportunities, including reinvestment in the brand, IT platforms, repurchase of regional development territories, merger or acquisition opportunities, and additional stock repurchase programs.
• Remediate the material weakness in internal controls over financial reporting by designing, implementing, and maintaining enhanced controls for non-routine transactions and impairment charges.
• Continue to defend against multiple lawsuits filed in California alleging invasion of privacy, breach of fiduciary duty, and failure to provide a safe environment.
• Evaluate the impact of ASU 2023-09 (Income Taxes) for adoption in 2025.
• Evaluate the impact of ASU 2024-03 (Income Statement Expense Disaggregation) for adoption in 2027/2028.

Key Dates

Recommendation

The Joint Corp. shows mixed signals. While the refranchising strategy has successfully boosted overall net income and cash from investing activities, and the company is actively returning capital to shareholders through buybacks, the core continuing operations still report a loss. More concerning are the declines in comparable same-store sales and system-wide sales, indicating potential underlying operational challenges in the existing franchise base. The persistent material weakness in internal controls and ongoing litigation add a layer of uncertainty. Investors should hold to see if the refranchising strategy fully stabilizes the business and if the company can reverse the negative sales trends in its continuing operations, while also addressing internal control deficiencies.

Keywords

chiropractic, franchising, SEC 10-Q, refranchising, clinic sales, stock repurchase, financial results, corporate governance, internal controls, labor shortage, inflation, healthcare, wellness, JYNT